Jesterone dimer, a synthetic derivative of the fungal metabolite jesterone, blocks activation of transcription factor nuclear factor κB by inhibiting the inhibitor of κB kinase

被引:45
作者
Liang, MC
Bardhan, S
Li, CM
Pace, EA
Porco, JA
Gilmore, TD
机构
[1] Boston Univ, Dept Biol, Boston, MA 02215 USA
[2] Boston Univ, Dept Chem, Boston, MA 02215 USA
[3] Boston Univ, Ctr Chem Methodol & Lib Dev, Boston, MA 02215 USA
关键词
D O I
10.1124/mol.64.1.123
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Rel/nuclear factor-kappaB (NF-kappaB) transcription factors control a variety of cellular processes, such as cell growth and apoptosis, and are continually activated in many human diseases, including chronic inflammatory diseases and cancer. Jesterone dimer (JD) is a synthetic derivative of the natural fungal metabolite jesterone, and JD has previously been shown to be cytotoxic in select tumor cell lines. In this report, we demonstrate that JD is a potent inhibitor of the activation of transcription factor NF-kappaB. Namely, JD inhibits tumor necrosis factor-alpha-induced activation of NF-kappaB in mouse 3T3 and human HeLa cells. JD seems to block the induction of the NF-kappaB pathway by inhibiting the inhibitor of kappaB kinase (IKK); that is, treatment of cells with JD blocks phosphorylation of IkappaBalpha, inhibits the activity of a constitutively active form of the IKKbeta catalytic subunit, and converts IKKbeta to stable high molecular mass forms. Like JD, a JD-related epoxyquinoid (isotorreyanic acid) inhibits activation of NF-kappaB at 20 muM, whereas several other epoxyquinoids that are related to JD, including its parent compound jesterone, do not block activation of NF-kappaB at this concentration. Finally, JD inhibits both proliferation and DNA binding by REL-containing complexes in the human lymphoma SUDHL-4 cell line, and JD activates caspase-3 activity in these cells. In summary, these results suggest that JD induces apoptosis in tumor cells through a mechanism that involves the inhibition of Rel/NF-kappaB activity and demonstrate the usefulness of assessing the bioactivity of synthetic derivatives of natural products.
引用
收藏
页码:123 / 131
页数:9
相关论文
共 34 条
[1]   Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells [J].
Bargou, RC ;
Emmerich, F ;
Krappmann, D ;
Bommert, K ;
Mapara, MY ;
Arnold, W ;
Royer, HD ;
Grinstein, E ;
Greiner, A ;
Scheidereit, C ;
Dörken, B .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (12) :2961-2969
[2]   Control of apoptosis by Rel/NF-κB transcription factors [J].
Barkett, M ;
Gilmore, TD .
ONCOGENE, 1999, 18 (49) :6910-6924
[3]   Three mutations in v-Rel render it resistant to cleavage by cell-death protease caspase-3 [J].
Barkett, M ;
Dooher, JE ;
Lemonnier, L ;
Simmons, L ;
Scarpati, JN ;
Wang, Y ;
Gilmore, TD .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2001, 1526 (01) :25-36
[4]   Natural products as targeted modulators of the nuclear factor-κB pathway [J].
Bremner, P ;
Heinrich, M .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2002, 54 (04) :453-472
[5]   CENTRAL OF I-KAPPA-B-ALPHA PROTEOLYSIS BY SITE-SPECIFIC, SIGNAL-INDUCED PHOSPHORYLATION [J].
BROWN, K ;
GERSTBERGER, S ;
CARLSON, L ;
FRANZOSO, G ;
SIEBENLIST, U .
SCIENCE, 1995, 267 (5203) :1485-1488
[6]   Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells [J].
Davis, RE ;
Brown, KD ;
Siebenlist, U ;
Staudt, LM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (12) :1861-1874
[7]   Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway [J].
Epinat, JC ;
Gilmore, TD .
ONCOGENE, 1999, 18 (49) :6896-6909
[8]   Cycloepoxydon, 1-hydroxy-2-hydroxymethyl-3-pent-1-enylbenzene and 1-hydroxy-2-hydroxymethyl-3-pent-1,3-dienylbenzene, new inhibitors of eukaryotic signal transduction [J].
Gehrt, A ;
Erkel, G ;
Anke, T ;
Sterner, O .
JOURNAL OF ANTIBIOTICS, 1998, 51 (05) :455-463
[9]   Missing pieces in the NF-κB puzzle [J].
Ghosh, S ;
Karin, M .
CELL, 2002, 109 :S81-S96
[10]   Rel/NF-κB/IκB signal transduction in the generation and treatment of human cancer [J].
Gilmore, T ;
Gapuzan, ME ;
Kalaitzidis, D ;
Starczynowski, D .
CANCER LETTERS, 2002, 181 (01) :1-9